Irish patients lose out on cancer care
New figures have revealed that patients in Ireland, both public and private, have far less access to new cancer medicines than other Europeans
The extent to which Irish patients – both public and private – are being denied access to innovative new cancer medicines are laid bare in new figures.
Just 20 per cent of such medicines launched internationally in 2014 and 2015 were available to Irish patients by 2016. The figure compares to 76 per cent in Germany and Austria. In Denmark, 67 per cent were reimbursed.
The situation affects public patients and those with ...
